AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1806467
Drug: Parlodel R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parlodel R (conventional bromocriptine) 2.5 mg b.i.d. for 2 weeks, then doubled for 2 weeks
Trial: 1806467
Drug: Parlodel SRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parlodel SRO (slow-release bromocriptine) 5 mg once daily for 2 weeks, then doubled for 2 weeks
Trial: 1806467
Drug: Parlodel SRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parlodel SRO (slow-release bromocriptine) 2.5-10 mg daily for 6 months
Trial: 25975969
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg bolus over 5 minutes, followed by 1.5 mg/kg/h continuous infusion until end of surgery)
Trial: 24093844
Drug: ivabradine 7.5
RxNorm normalized name: ivabradine 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 7.5 mg twice a day
Trial: 16388984
Drug: CMV gB
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV gB vaccine
Trial: 12804020
Drug: Algal extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algal extract in safflower oil (2 mg of astaxanthin each, 3 gelcaps per day)
Trial: 10826575
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SR49059
Trial: 10826575
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg SR49059
Trial: 1577222
Drug: Once-a-day morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-day morning administration of 40 mg famotidine
Trial: 1577222
Drug: Once-a-day bedtime
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-day bedtime administration of 40 mg famotidine
Trial: 29706701
Drug: Spinal decompression
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal decompression therapy
Trial: 15785149
Drug: Ximelagatran (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (fixed dose)
Trial: 7778530
Drug: Delapril 15
RxNorm normalized name: Delapril
DrugBank: Delapril (DB13312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril 15 mg twice daily
Trial: 2318113
Drug: Threefold basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threefold basal immunosuppression (low-dose ciclosporin, azathioprine, and prednisolone)
Trial: 2318113
Drug: Fourfold basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourfold basal immunosuppression (with additional poly- or monoclonal antibodies)
Trial: 2318113
Drug: Additional antirejection
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional antirejection treatment with poly- or monoclonal antibodies
Trial: 7350888
Drug: Electronic intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic intravenous (IV) rate controller
Trial: 31915038
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet and resistance training combination
Trial: 27458993
Drug: Artesunate combination
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate combination therapy (ACT)
Trial: 21558397
Drug: Topical CUR61414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical CUR61414 in preclinical studies
Trial: 19465442
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone (500 microg twice daily from a Diskus inhaler)
Trial: 19465442
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (30 mg daily)
Trial: 15202770
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral lorazepam (0.5 mg or 1 mg)
Trial: 9537307
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of bombesin (0.09 nmol/kg ideal weight/h)
Trial: 2225536
Drug: 0.1% betamethasone‐17‐valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone‐17‐valerate cream (Betnovate)
Trial: 2225536
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol proprionate cream (Dermovate)
Trial: 2225536
Drug: base cream
RxNorm normalized name: U-Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: base cream
Trial: 29122156
Drug: Reslizumab 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reslizumab 3.0 mg/kg intravenously every 4 weeks for up to 24 months
Trial: 25744962
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) plus Healthy Lifestyles intervention
Trial: 25744962
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) plus predominantly telephone-based intervention
Trial: 23512860
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle intervention (ILI) on statin therapy
Trial: 23512860
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care on statin therapy
Trial: 23512860
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle intervention (ILI) not on statin therapy
Trial: 19704175
Drug: TMC278 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 25 mg
Trial: 19704175
Drug: TMC278 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 50 mg
Trial: 19704175
Drug: TMC278 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 150 mg
Trial: 13129464
Drug: FOS-supplemented infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOS-supplemented infant cereal (0.75 g FOS per serving)
Trial: 6347749
Drug: Ketotifen (0.5-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (0.5-1 mg b.i.d. for 12 weeks)
Trial: 2582325
Drug: Intensive cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cyclic therapy using either the same drugs of the induction regimen or rotating combinations of alternative drugs (e.g., mAMSA, 5-AZA, HD-Ara C)
Trial: 23753021
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment
Trial: 2582325
Drug: Induction or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction or maintenance treatment
Trial: 29190004
Drug: Tailored dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A)
Trial: 29190004
Drug: Fixed doses
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed doses of the same regimen (group B)
Trial: 18199863
Drug: Etanercept (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.8 mg/kg, max 50 mg)
Trial: 18199863
Drug: Etanercept (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (after 24 weeks of open-label treatment)
Trial: 18199863
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after 24 weeks of open-label treatment)
Trial: 18199863
Drug: Etanercept (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (open-label treatment)
Trial: 12575908
Drug: Whey preload
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey preload (48 g, 1700 kJ liquid preload)
Trial: 10232292
Drug: Active catecholamine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active catecholamine depletion via oral administration of 5 g alpha‐methylparatyrosine
Trial: 10232292
Drug: Sham catecholamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham catecholamine depletion via oral administration of 250 mg diphenhydramine hydrochloride
Trial: 8734351
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (1000 mg)
Trial: 27112475
Drug: Arterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arterial infusion with 8 ml of 1% methylene blue
Trial: 27112475
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without artery infusion
Trial: 22627477
Drug: PF‐04523655 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04523655 (50 to 3000 μg)
Trial: 19067709
Drug: Two-compound scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound scalp formulation (calcipotriol 50 microg g(‐1) plus betamethasone 0.5 mg g(‐1))
Trial: 19067709
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate 0.5 mg g(‐1)
Trial: 19067709
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg g(‐1)
Trial: 17976797
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tramadol ingested 1.5 h before oxycodone
Trial: 17976797
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg immediate-release oxycodone orally
Trial: 12593694
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g intravenously before operation and 1 g intravenously at the end of cardiopulmonary bypass (Group 1)
Trial: 12593694
Drug: Cefazolin 2
RxNorm normalized name: cefazolin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 2 g intravenously before operation, followed by continuous intravenous infusion at 20 mg/min throughout surgery (Group 2)
Trial: 12593694
Drug: Cefazolin 3
RxNorm normalized name: cefazolin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 3 g intravenously before operation, followed by continuous intravenous infusion at 15 mg/min throughout surgery (Group 3)
Trial: 10491209
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D receptor genotype (TaqI, ApaI)
Trial: 10491209
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D receptor polymorphisms (TaqI and ApaI)
Trial: 8708714
Drug: Diethylstilbestrol (DES,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES, 1 mg three times daily)
Trial: 6293321
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen producing less depression and fatigue
Trial: 6293321
Drug: Other chemotherapy
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapy regimen
Trial: 12185396
Drug: Citalopram 40
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 40 mg daily
Trial: 8118471
Drug: Citalopram 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 60 mg daily
Trial: 12185396
Drug: Citalopram 10
RxNorm normalized name: citalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 10 mg daily
Trial: 12185396
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg daily
Trial: 12185396
Drug: Citalopram 40
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 40 mg and 60 mg daily
Trial: 30652031
Drug: Combined genotypes
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined genotypes ProAla + AlaAla and GC + CC
Trial: 27835716
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment for 8 weeks
Trial: 27835716
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment for patients with objective memory dysfunction at baseline (n = 16)
Trial: 21847713
Drug: 0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/day RPM
Trial: 21847713
Drug: 2.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/day RPM
Trial: 21847713
Drug: 3.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g/day RPM
Trial: 21847713
Drug: 4.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g/day RPM
Trial: 20303474
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg single oral dose of D-cycloserine (DCS)
Trial: 7894879
Drug: Amisulpride 100
RxNorm normalized name: amisulpride 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 100 mg/d
Trial: 7894879
Drug: Amisulpride 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 300 mg/d
Trial: 2484467
Drug: MSD vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSD vaccine (2 doses)
Trial: 2484467
Drug: Pasteur vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasteur vaccine (3 doses)
Trial: 25486932
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence information (AI) provided to physician
Trial: 25486932
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence information (AI) and motivational interviewing (MI)
Trial: 23023528
Drug: Fenretinide 300
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide 300 mg daily
Trial: 23023528
Drug: Fenretinide 100
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide 100 mg daily
Trial: 15710069
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day + UDCA 300 mg/day
Trial: 15710069
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day + UDCA 300 mg/day
Trial: 11098961
Drug: Hypocaloric feeding
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric feeding (1 L containing 70 g protein and 1000 kcal)
Trial: 11098961
Drug: Standard weight‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight‐based regimen (25 kcal and 1.5 g protein/kg dry weight)
Trial: 8159594
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine in chocolate wafer
Trial: 8159594
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine mixed with Isocal
Trial: 2851016
Drug: Enoxaparine 60
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparine 60 mg
Trial: 2851016
Drug: Enoxaparine 80
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparine 80 mg
Trial: 28324706
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40IU) with positive emotion inductions
Trial: 27367855
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 μg Se as selenized yeast) and Coenzyme Q10 (200 mg) supplementation for four years
Trial: 19277942
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration (WBV) training, 30 Hz, 4 mm amplitude, thrice weekly for 3 min for 4 weeks
Trial: 7959554
Drug: Preoperative course
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative course of chemotherapy and radiotherapy
Trial: 2954497
Drug: Clemastine 1
RxNorm normalized name: clemastine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 1 mg twice daily
Trial: 31678343
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day vortioxetine
Trial: 31678343
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day vortioxetine
Trial: 31678343
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day escitalopram
Trial: 27720136
Drug: Sunitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib plus IMA901 (4·13 mg) and granulocyte macrophage colony-stimulating factor (75 μg), with cyclophosphamide (300 mg/m2) 3 days before the first vaccination.
Trial: 27720136
Drug: Sunitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib monotherapy (50 mg orally once daily).
Trial: 24925120
Drug: Full-dose nuts
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose nuts (50-100 g/d)
Trial: 24925120
Drug: Half-dose nuts
RxNorm normalized name: Half Beta-Prograne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose nuts with half-dose muffins
Trial: 24925120
Drug: Full-dose nuts
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose nuts
Trial: 19076630
Drug: Efalizumab, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab, 1 mg/kg/week administered subcutaneously for up to 15 months
Trial: 16189176
Drug: GH and
RxNorm normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH and acipimox co-administration
Trial: 16189176
Drug: Acipimox administration
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox administration
Trial: 14624289
Drug: Nimesulide 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 300 mg
Trial: 10951149
Drug: Mite allergen
RxNorm normalized name: house dust mite allergen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mite allergen avoidance measures (encasing mattresses and pillows; weekly hot wash of bedding; frequent vacuum cleaning; cleaning/removing soft toys and carpets; no pets allowed)
Trial: 10160375
Drug: Ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin treatment (five doses in Sierra Leone, three doses in Nigeria)
Trial: 8296531
Drug: L-threonine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threonine at 6 g/day
Trial: 3711553
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) aqueous spray, 42 mcg per spray
Trial: 3711553
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) aerosol spray, 42 mcg per spray
Trial: 29713137
Drug: Parent Child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent Child Interaction Therapy (individualized mastery‐based coaching; PCIT)
Trial: 19884812
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy (daily local mud packs and bicarbonate-sulfate mineral bath water) for 2 weeks
Trial: 10807894
Drug: L/MCT diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/MCT diet (equal quantities of LCT and MCT)
Trial: 8862439
Drug: 10, 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 25, 50, or 75 micrograms/kg/day of rhIL-11 administered subcutaneously for 14 consecutive days
Trial: 8862439
Drug: rhIL-11 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 treatment at the two highest doses
Trial: 8862439
Drug: rhIL-11 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 treatment
Trial: 8862439
Drug: rhIL-11 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 therapy at the highest dose
Trial: 8862439
Drug: rhIL-11 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 administration
Trial: 4091995
Drug: Meptazinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (200 mg)
Trial: 4091995
Drug: Dextropropoxyphene/paracetamol mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg)